Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) were down 3.7% on Monday . The stock traded as low as $2.29 and last traded at $2.31. Approximately 325,324 shares changed hands during trading, a decline of 93% from the average daily volume of 4,804,619 shares. The stock had previously closed at $2.40.
Lexicon Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. The company has a 50 day moving average price of $2.36 and a two-hundred day moving average price of $1.63.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. TIAA Trust National Association acquired a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $29,000. SG Americas Securities LLC acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter valued at $64,000. Swiss National Bank raised its stake in Lexicon Pharmaceuticals by 4.4% in the 3rd quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 10,300 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in Lexicon Pharmaceuticals by 160.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 24,400 shares during the last quarter. Finally, KWB Wealth acquired a new position in Lexicon Pharmaceuticals in the 4th quarter valued at $62,000. 74.70% of the stock is owned by institutional investors and hedge funds.
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Featured Stories
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
